行情

FGEN

FGEN

纤维蛋白原
NASDAQ

实时行情|Nasdaq Last Sale

44.35
-0.24
-0.54%
盘后: 44.35 0 0.00% 17:45 01/17 EST
开盘
44.96
昨收
44.59
最高
45.21
最低
44.30
成交量
83.51万
成交额
--
52周最高
61.23
52周最低
32.33
市值
38.68亿
市盈率(TTM)
107.44
分时
5日
1月
3月
1年
5年

分析师评级

8位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

FGEN 新闻

  • 2019 Review: Top Hedge Fund Stocks vs. FibroGen Inc (FGEN)
  • Insider Monkey.5天前
  • Four months after CEO's death, biotech company names Lilly vet as leader
  • American City Business Journals.01/06 23:03
  • FibroGen Appoints Enrique Conterno as Its New CEO
  • MotleyFool.com.01/06 17:54
  • New CEO at FibroGen
  • Seeking Alpha - Article.01/06 13:09

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

FGEN 简况

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.
展开

Webull提供FibroGen Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。